A Phase 3, Double-Blind, Randomized, Two-Period, Multicenter, Placebo-Controlled, Efficacy and Safety Study of JNT-517 for the Treatment of Participants With Phenylketonuria
Latest Information Update: 10 Jun 2025
At a glance
- Drugs JNT-517 (Primary)
- Indications Phenylketonuria
- Focus Registrational; Therapeutic Use
- Sponsors Jnana Therapeutics; Otsuka Pharmaceutical Development & Commercialization
Most Recent Events
- 22 May 2025 New trial record